Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study.
Howell D et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14513. [Epub ahead of print].

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.
Lisenko K et al. BMC Cancer. 2017 Feb 22;17(1):151. doi: 10.1186/s12885-017-3137-4.

Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.
Mainou M et al. Eur J Haematol. 2017 Feb 8. doi: 10.1111/ejh.12868. [Epub ahead of print].

Patients’ Experiences With Multiple Myeloma: A Meta-Aggregation of Qualitative Studies.
Hauksdóttir B et al. Oncol Nurs Forum. 2017 Mar 1;44(2):E64-E81. doi: 10.1188/17.ONF.E64-E81.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK et al. J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Landgren O et al. J Intern Med. 2017 Feb 16. doi: 10.1111/joim.12590. [Epub ahead of print].

Multiple myeloma.
Chavda SJ et al. Br J Hosp Med (Lond). 2017 Feb 2;78(2):C21-C27. doi: 10.12968/hmed.2017.78.2.C21.

Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC).
Birmann BM et al. Cancer Epidemiol Biomarkers Prev. 2017 Feb 21. pii: cebp.0762.2016. doi: 10.1158/1055-9965.EPI-16-0762-T. [Epub ahead of print].

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
Tandon N et al. Blood Cancer J. 2017 Feb 17;7(2):e528. doi: 10.1038/bcj.2017.13.

Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma.
Lee N et al. Blood Cancer J. 2017 Feb 17;7(2):e530. doi: 10.1038/bcj.2017.14.

Monoclonal antibody therapy in multiple myeloma.
Touzeau C et al. Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.60. [Epub ahead of print].

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA et al. Drugs. 2017 Feb 16. doi: 10.1007/s40265-017-0689-1. [Epub ahead of print].

Maintenance therapy in multiple myeloma.
Mewawalla P et al. Ther Adv Hematol. 2017 Feb;8(2):71-79. doi: 10.1177/2040620716677244.

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.
Raza S et al. Ther Adv Hematol. 2017 Feb;8(2):55-70. doi: 10.1177/2040620716680548.

New monoclonal antibodies on the horizon in multiple myeloma.
O’Donnell EK et al. Ther Adv Hematol. 2017 Feb;8(2):41-53. doi: 10.1177/2040620716682490.

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME et al. Clin Epigenetics. 2017 Feb 10;9:17. doi: 10.1186/s13148-017-0319-5. eCollection 2017.

Multiple Myeloma and the immune microenvironment.
Kawano Y et al. Curr Cancer Drug Targets. 2017 Feb 13. doi: 10.2174/1568009617666170214102301. [Epub ahead of print].

Targeting the immune niche within the bone marrow microenvironment: The rise of immunotherapy in Multiple Myeloma.
Podar K et al. Curr Cancer Drug Targets. 2017 Feb 13. doi: 10.2174/1568009617666170214103834. [Epub ahead of print].

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S et al. Curr Cancer Drug Targets. 2017 Feb 13. doi: 10.2174/1568009617666170214104426. [Epub ahead of print].

Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP et al. Expert Rev Hematol. 2017 Feb 1:1-9. doi: 10.1080/17474086.2017.1280388. [Epub ahead of print].

Statins in Multiple Myeloma: Survival Benefit or Immortal Time Bias?
Suissa S et al. J Clin Oncol. 2017 Feb 6:JCO2016709725. doi: 10.1200/JCO.2016.70.9725. [Epub ahead of print].

m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T et al. Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14529. [Epub ahead of print].

A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?
Green DJ et al. Curr Hematol Malig Rep. 2017 Jan 31. doi: 10.1007/s11899-017-0365-2. [Epub ahead of print].

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period.
Oberoi D et al. J Cancer Surviv. 2017 Jan 31. doi: 10.1007/s11764-016-0591-y. [Epub ahead of print].

Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Chen CC et al. J Manag Care Spec Pharm. 2017 Feb;23(2):236-246. doi: 10.18553/jmcp.2017.23.2.236.

Multiple Myeloma Mentorship: Bridging Communication and Educational Gaps.
Faiman B et al. Clin J Oncol Nurs. 2017 Feb 1;21(1):99-103. doi: 10.1188/17.CJON.99-103.